Skip to main content

Table 7 PICOT question 4: influence of ICS particle size on asthma outcomes: summary of results of matched database studies

From: Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group—European Academy of Allergy and Clinical Immunology Task Force

Reference

Outcomes

Treatments

Population

Database

Results

Van Aalderen et al. [67]

Clinical

BDP pMDI

St versus EF

Initiation

Step-up

Vs LABA

Children 5–11

UK (CPRD)

US (Optuminsight)

EF > St

EF = adding LABA

Price et al. [70]

Clinical

BDP pMDI

St versus EF

Initiation

Switch

12–80

UK GPRD CPRD

EF > St

Price et al. [71]

Clinical

pMDI

St FP versus EF BDP

Initiation

Step-up

5–60

UK GPRD

EF ≥ St at lower doses

Barnes et al. [40]

Clinical

BDP pMDI

St versus EF

Initiation

Step-up

5–60

UK GPRD

EF > St

Martin et al. [68]

C-E

BDP/FP pMDI

St versus EF

Initiation

12–60/12–80

UK/US

EF dominant

Colice et al. [69]

C-E

pMDI

St FP versus EF BDP

Initiation

Step-up

12–80

UK/US

EF ≥ St at lower doses and costs

Price et al. [32]

C-E

St FP-SAL versus EF BDP-FOR

18–80

UK GPRD CPRD

EF ≥ St at lower doses

EF dominant

  1. EF extra-fine, St standard size, BDP beclomethasone dipropionate, SAL salmeterol; FOR, formoterol, FP fluticasone propionate, pMDI pressurized metered-dose inhaler